Clinical trials: Cirrhosis
Decompensated Hepatitis B Cirrhosis
Fuzheng Huayu Tablets Reduce the Occurrence of Re-Decompensation Events in Patients With First Decompensation of Hepatitis B-Related Liver Cirrhosis: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study
This study aims to conduct a prospective, multicenter, double-blind, randomized, placebo-controlled trial. The planned sample size is 432 patients, with the ratio of the Fuzheng Huayu group to the placebo control group being 1:1.
- Trial name
- FZHYRORDFDHBLC (NCT07017426)
- Testing
- Fuzheng Huayu tablets
- Volunteers
- 432 people
- Sponsor
- Zhiyun Yang
Cirrhosis Due to Hepatitis B
A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis
Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents have been claimed equivalent in treatment, there are no head to head trials available in the literature about there effectiveness in HBV…
- Trial name
- NCT02238860
- Testing
- Entacavir, Tenofovir
- Where
- Pakistan
- Volunteers
- 100 people
- Sponsor
- Asian Institute Of Medical Sciences
Cirrhosis, Diabetes Mellitus
Efficacy of Esmolol in the Identification of Cardiovascular Disorders by Cirrhosis, Diabetes Mellitus and Cardiotoxic Treatments
The purpose of this study is to assess the superiority of esmolol echocardiography over conventional echocardiography in the diagnosis of subclinical myocardial involvement associated with diabetes mellitus 2, cirrhosis and…
- Conditions
- Cirrhosis, Diabetes Mellitus, Oncologic Disorders
- Trial name
- CIBERbBECHO (NCT05769868)
- Testing
- Esmolol Injection [Brevibloc]
- Where
- 6 sites in Spain
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Consorcio Centro de Investigación Biomédica en Red (CIBER)
Ascitic Fluid, Microbiota, Microbiota
Ascitic Fluid Microbiome in Liver Cirrhosis
Ascitic fluid microbiome is going to be investigated in this study by using internal transcripted spacer (ITS) and 16S ribosomal RNA (rRNA) polymerase chain reaction (PCR) and sequencing as conventional culture methods are…
- Conditions
- Ascitic Fluid, Microbiota, Microbiota, Sequence Analysis, Polymerase Chain Reaction
- Trial name
- NCT02813590
- Testing
- Ascitic fluid puncture, Skin swaps from puncture side, Stool samples
- Where
- Austria
- Sponsor
- Medical University of Graz
Esophageal and Gastric Varices
Comparison of Endoscopic Band Ligation Plus 24-hour Versus 72-hour Terlipressin Therapy
In the Western world, liver cirrhosis is a significant issue. Acute variceal bleeding (AVB) is a considerable complication of cirrhosis associated with high mortality.
- Trial name
- NCT05331768
- Testing
- banding ligation plus terlipressin infusion
- Where
- Mexico
- Volunteers
- 109 people, healthy volunteers welcome
- Sponsor
- Instituto Mexicano del Seguro Social
Liver Cirrhosis and Hepatoma., Gastric Variceal Bleeding
Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding
Gastric variceal bleeding has a very high rebleeding rate even after endoscopic variceal injection of cyanoacrylate (GVO) which is considered the first choice of endoscopic treatment.
- Trial name
- GVO-nadolol (NCT00567216)
- Testing
- Nadolol
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Taipei Veterans General Hospital, Taiwan
Liver Cirrhosis
Lean Mass Evaluation of Cirrhotic Patients With Ascites With the Use DXA
Malnutrition due to liver disease is common, however, their detection is difficult. The parameters used for nutritional assessment in clinical practice have limited use in this patient population.
- Trial name
- BCECPA (NCT02421848)
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- University of Sao Paulo
Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
The aim of this study is to assess the prevalence of nonalcoholic fatty liver disease (NAFLD) in patients with type 1 diabetes receiving care at Joslin clinic using noninvasive imaging and serum-based methods with the goal of…
- Conditions
- Nonalcoholic Fatty Liver, Nonalcoholic Steatohepatitis, Fibrosis, Liver, Type 1 Diabetes
- Trial name
- NCT04595474
- Testing
- Transient Elastography
- Where
- United States
- Volunteers
- 533 people
- Sponsor
- Joslin Diabetes Center
Hepatic Encephalopathy, Acute-On-Chronic Liver Failure
Role of Bilirubin Molecular Species in Hepatic Encephalopathy and Acute-on-chronic Liver Failure
It has been identified that impaired liver function, as occurs in patients with liver cirrhosis, prevents proper conjugation of glucuronic acid with bilirubin; as a result, unconjugated bilirubin accumulates in the blood, and…
- Trial name
- NCT05566548
- Testing
- Liquid Chromatography-Mass Spectrometry Method to identify bilirubin molecular species
- Where
- Mexico
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Medica Sur Clinic & Foundation
Biliary Cirrhosis, Primary
Family Studies in Primary Biliary Cirrhosis (PBC)
Primary biliary cirrhosis (PBC) is a chronic liver disease primarily affecting middle age women. It is characterized by immune-mediated damage to cells lining the tiny bile ducts within the liver.
- Trial name
- NCT00242125
- Where
- Canada
- Volunteers
- 3,000 people
- Sponsor
- University Health Network, Toronto
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
HIV, Hepatitis C
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
HIV infection exerts a negative impact on the course of HCV infection. Co-infected individuals progress more rapidly to liver fibrosis, cirrhosis and ESLD compared to those infected with HCV alone.
- Conditions
- HIV, Hepatitis C, Liver Fibrosis
- Trial name
- NCT01231685
- Testing
- Raltegravir, Ritonavir-boosted protease inhibitor
- Where
- 3 sites in Canada
- Volunteers
- 9 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Gastroesophageal Varices, Cirrhosis
The Effect of Hepatic Vein Pressure Gradient(HVPG)-Guided Therapy in Cirrhotic Patients With Esophagogastric Varices
The purpose of the study is to compare the effect of HVPG-guided individualized therapy and non-HVPG guided traditional therapy in cirrhotic patients for secondary prophylaxis.
- Trial name
- NCT02638415
- Testing
- HVPG-guided therapy, routine therapy, Carvedilol
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Shanghai Zhongshan Hospital
Pruritus
Global Linerixibat Itch Study of Efficacy and Safety in Primary Biliary Cholangitis (PBC) (GLISTEN)
This is a 2-part study in PBC participants with cholestatic pruritus and will evaluate the efficacy, safety and impact on health-related quality of life of linerixibat compared with placebo.
- Trial name
- NCT04950127
- Testing
- Linerixibat
- Where
- 5 sites in Germany, United Kingdom
- Volunteers
- 238 people
- Sponsor
- GlaxoSmithKline
Hepatic Encephalopathy
Flicker App for Minimal Hepatic Encephalopathy
There is a great unmet clinical need for improved screening for MHE in patients with cirrhosis. We will demonstrate that the Flicker-App can be used in clinic as well as at home by patients with cirrhosis to measure CFF, a proven…
- Trial name
- NCT04415294
- Testing
- Critical flicker frequency
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Washington
Portal Vein Thrombosis
Efficacy and Safety of Rivaroxaban in the Management of Acute Non-neoplastic PVT Compensated Cirrhosis
-Rivaroxaban is factor Xa inhibitor
- Trial name
- NCT03193502
- Testing
- rivaroxaban
- Where
- Egypt
- Volunteers
- 40 people
- Sponsor
- Sherief Abd-Elsalam
Hepatitis B, Portal Hypertension
Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
To evaluate whether atorvastatin can improve portal hypertension in patients with chronic hepatitis B related compensated cirrhosis with portal hypertension
- Trial name
- STAPH (NCT05483894)
- Testing
- Atorvastatin 10mg
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
Hepatic Encephalopathy
Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhotic Patients
The aim of this study is to compare the efficacy and safety of colistin versus lactulose for secondary prophylaxis of overt hepatic encephalopathy in patients with liver cirrhosis.
- Trial name
- NCT05279586
- Testing
- lactulose, colistin
- Volunteers
- 316 people
- Sponsor
- Madonna Magdy Fahmy
Morbid Obesity, Non Alcoholic Steatohepatitis
Non Invasive Measurements of Fibrosis, Inflammation and Steatohepatitis in Morbidly Obese Patients
Abstract: Fatty liver most frequently corresponds to a fat overload of the liver. It is usually classified as alcoholic steatosis or non-alcoholic steatosis.
- Trial name
- FIRM (NCT01695083)
- Where
- France
- Volunteers
- 186 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Biliary Cholangitis (PBC)
Using Digital Health Technology to Monitor Patients With Primary Biliary Cholangitis (PBC)
The purpose of this study is to explore the use of digital health technology for measuring symptoms and daily health in people with primary biliary cholangitis (PBC).
- Trial name
- NCT07631442
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.